S. Florentinus

756 total citations
36 papers, 527 citations indexed

About

S. Florentinus is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, S. Florentinus has authored 36 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 17 papers in Genetics and 13 papers in Hematology. Recurrent topics in S. Florentinus's work include Rheumatoid Arthritis Research and Therapies (25 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Autoimmune and Inflammatory Disorders Research (13 papers). S. Florentinus is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (25 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Autoimmune and Inflammatory Disorders Research (13 papers). S. Florentinus collaborates with scholars based in United States, Germany and Netherlands. S. Florentinus's co-authors include H. Küpper, Udayasankar Arulmani, Roy Fleischmann, Alan Kivitz, Suchitrita S. Rathmann, Sandra Goss, Gerd‐Rüdiger Burmester, Josef S Smolen, Hubert G. M. Leufkens and Eibert R. Heerdink and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

S. Florentinus

34 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Florentinus United States 13 364 174 107 107 52 36 527
H.L.M. Brus Netherlands 10 471 1.3× 189 1.1× 111 1.0× 102 1.0× 53 1.0× 18 594
Olav Bjørneboe Norway 11 438 1.2× 153 0.9× 105 1.0× 105 1.0× 48 0.9× 19 674
Angela Nagel Germany 11 194 0.5× 51 0.3× 92 0.9× 174 1.6× 36 0.7× 28 528
Alex Limanni United States 8 165 0.5× 107 0.6× 76 0.7× 33 0.3× 55 1.1× 13 364
Ani John United States 14 416 1.1× 166 1.0× 107 1.0× 103 1.0× 23 0.4× 30 575
Anne‐Barbara Mongey United States 12 274 0.8× 65 0.4× 92 0.9× 67 0.6× 56 1.1× 21 455
Moetaza M. Soliman Egypt 9 281 0.8× 126 0.7× 176 1.6× 82 0.8× 30 0.6× 24 449
A Kapelle Germany 4 389 1.1× 128 0.7× 155 1.4× 51 0.5× 18 0.3× 7 503
Gary Kunkel United States 10 318 0.9× 202 1.2× 111 1.0× 74 0.7× 21 0.4× 22 552
Patrick Seys Netherlands 8 423 1.2× 163 0.9× 61 0.6× 100 0.9× 34 0.7× 9 564

Countries citing papers authored by S. Florentinus

Since Specialization
Citations

This map shows the geographic impact of S. Florentinus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Florentinus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Florentinus more than expected).

Fields of papers citing papers by S. Florentinus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Florentinus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Florentinus. The network helps show where S. Florentinus may publish in the future.

Co-authorship network of co-authors of S. Florentinus

This figure shows the co-authorship network connecting the top 25 collaborators of S. Florentinus. A scholar is included among the top collaborators of S. Florentinus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Florentinus. S. Florentinus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aletaha, Daniel, Jen‐Fue Maa, Su Chen, et al.. (2019). Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 78(12). 1609–1615. 39 indexed citations
2.
Aletaha, Daniel, et al.. (2019). Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. Seminars in Arthritis and Rheumatism. 50(2). 276–284. 18 indexed citations
3.
4.
Kavanaugh, Arthur, Ronald van Vollenhoven, Roy Fleischmann, et al.. (2017). Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Annals of the Rheumatic Diseases. 77(2). 289–292. 20 indexed citations
5.
Möller, Burkhard, Judith Everts‐Graber, S. Florentinus, et al.. (2017). Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. Arthritis Care & Research. 70(6). 861–868. 17 indexed citations
6.
Keystone, Edward, Ferdinand C. Breedveld, Désirée van der Heijde, et al.. (2017). Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 3(2). e000445–e000445. 8 indexed citations
7.
8.
Landewé, Robert, Josef S Smolen, S. Florentinus, et al.. (2015). Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Research & Therapy. 17(1). 133–133. 11 indexed citations
9.
10.
Burmester, Gerd‐Rüdiger, Alan Kivitz, H. Küpper, et al.. (2014). Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Annals of the Rheumatic Diseases. 74(6). 1037–1044. 183 indexed citations
11.
Keystone, E C, F. C. Breedveld, D. van der Heijde, et al.. (2013). Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial. Data Archiving and Networked Services (DANS). 65. 1 indexed citations
12.
13.
Fleischmann, Roy, Alan Kivitz, Ronald van Vollenhoven, et al.. (2013). SAT0006 No Differences in Patient-Reported Outcomes by Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly with Adalimumab: Results from the Concerto Trial. Annals of the Rheumatic Diseases. 72. A580–A581. 3 indexed citations
14.
Burmester, Gerd R, A. Kivitz, Ronald van Vollenhoven, et al.. (2013). THU0239 Methotrexate Dose has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial. Annals of the Rheumatic Diseases. 72. A246–A246. 2 indexed citations
15.
Keystone, Edward, FC Breedveld, D. van der Heijde, et al.. (2013). THU0190 Long-Term Impact of Delaying Combination Therapy with Adalimumab Plus Methotrexate by 2 Years in Patients with Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial. Annals of the Rheumatic Diseases. 72. A227–A228. 1 indexed citations
16.
Keystone, Edward, FC Breedveld, D. van der Heijde, et al.. (2013). THU0191 Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone. Annals of the Rheumatic Diseases. 72. A228–A228.
17.
18.
Florentinus, S., et al.. (2006). Linking community pharmacy dispensing data to prescribing data of general practitioners. BMC Medical Informatics and Decision Making. 6(1). 18–18. 23 indexed citations
19.
Florentinus, S., Eibert R. Heerdink, A. de Boer, Liset van Dijk, & Hubert G. M. Leufkens. (2005). The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiology and Drug Safety. 14(7). 437–441. 8 indexed citations
20.
Florentinus, S., et al.. (2005). Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. European Journal of Clinical Pharmacology. 61(2). 157–159. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H.L.M. Brus Breakdown of academic impact, for papers by Olav Bjørneboe Breakdown of academic impact, for papers by Angela Nagel Breakdown of academic impact, for papers by Alex Limanni Breakdown of academic impact, for papers by Ani John Breakdown of academic impact, for papers by Anne‐Barbara Mongey Breakdown of academic impact, for papers by Moetaza M. Soliman Breakdown of academic impact, for papers by A Kapelle Breakdown of academic impact, for papers by Gary Kunkel Breakdown of academic impact, for papers by Patrick Seys
Rankless by CCL
2026